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Abstract
Upon demyelination, transient expression of fibronectin precedes successful remyelination. How-
ever, in chronic demyelination observed in multiple sclerosis (MS), aggregates of fibronectin persist
and contribute to remyelination failure. Accordingly, removing fibronectin (aggregates) would con-
stitute an effective strategy for promoting remyelination. Matrix metalloproteinases (MMPs) are
enzymes known to remodel extracellular matrix components, including fibronectin. Here, we exam-
ined the ability of MMPs to degrade fibronectin aggregates. Our findings reveal that MMP7 cleaved
fibronectin aggregates resulting into a prominent 13 kDa EIIIA (16 kDa EDA)-containing fragment.
MMP7 was upregulated during lysolecithin-induced demyelination, indicating its potential for
endogenous fibronectin clearance. In contrast, the expression of proMMP7 was substantially
decreased in chronic active and inactive MS lesions compared with control white matter and remye-
linated MS lesions. Microglia and macrophages were major cellular sources of proMMP7 and IL-4-
activated, but not IFNg1LPS-activated, microglia and macrophages secreted significant levels of
proMMP7. Also, conditioned medium of IL-4-activated macrophages most efficiently cleaved fibro-
nectin aggregates upon MMP-activating conditions. Yet, coatings of MMP7-cleaved fibronectin
aggregate fragments inhibited oligodendrocyte maturation, indicating that further degradation and/
or clearance by phagocytosis is essential. These findings suggest that MMP7 cleaves fibronectin
aggregates, while reduced (pro)MMP7 levels in MS lesions contribute to their persistent presence.
Therefore, upregulating MMP7 levels may be key to remove remyelination-impairing fibronectin
aggregates in MS lesions.
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1 | INTRODUCTION
Myelination of axons is not only essential for saltatory nerve conduc-
tion, but also required for neuronal survival as myelin provides trophic
and metabolic support (Irvine & Blakemore, 2008; F€unfschilling et al.,
2012). Hence, the persistent loss of intact myelin, as observed in the
chronic demyelinating disease multiple sclerosis (MS), promotes
secondary axonal degeneration, significantly contributing to disease
progression (Compston & Coles, 2008; Irvine & Blakemore, 2008).
Therefore, regeneration of myelin (remyelination), is essential to sup-
port and retain axons, and to prevent progressive decline.
Remyelination is dependent on precise and timely regulation of local
signalling events, which control recruitment of activated oligodendro-
cyte progenitor cells (OPCs) to the demyelinated area and their subse-
quent differentiation into myelinating oligodendrocytes (Franklin &
ffrench-Constant, 2008). The extracellular matrix (ECM) is a major
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component of the signaling microenvironment and participates in the
regulation of OPC behavior, its remodeling serving as an effective mech-
anism to regulate repair. Specifically, following central nervous system
(CNS) demyelination, extensive ECM remodeling leads to alterations in
ECM expression profiles (Back et al., 2005; Zhao, Fancy, Franklin, &
ffrench-Constant, 2009; Lau et al., 2012; Hibbits, Yoshino, Le, & Arm-
strong, 2012; Stoffels et al., 2013). For example, following lysolecithin-
induced demyelination and in chronic-relapsing (cr-)EAE, remyelination-
impairing fibronectin and chrondroitin sulfate proteoglycans (CSPGs),
and remyelination-promoting laminin are readily expressed (Milner et al.,
2007; Lau et al., 2012; Stoffels et al., 2013). Evidently, the regulation
and transient expression of these distinct ECM molecules, is essential in
maintaining the proper physiological environment for timely develop-
ment of OPCs into mature, myelinating oligodendrocytes. Indeed, a dys-
balance in expression of these ECM entities contributes to an impaired
differentiation of OPCs, as observed in 70% of MS lesions (Lucchinetti
et al., 1999; Kuhlmann et al., 2008; Chang et al., 2012). More specifically,
in chronic MS lesions, but not in toxin-induced lesions, fibronectin is per-
sistently present as aggregates, which frustrates OPC differentiation,
and thereby impedes remyelination (Stoffels et al., 2013). Moreover,
fibronectin precludes the ability of laminin, also present in MS lesions
(Van Horssen, B€o, Vos, Virtanen, & de Vries, 2005), to facilitate myelin
membrane formation (Baron et al., 2014), emphasizing the necessity to
remove aggregated fibronectin to allow remyelination.
Interestingly, fibronectin mRNA is hardly present in chronic MS
lesions (Stoffels et al., 2013) and aggregates are formed extracellularly
(Mao & Schwarzbauer, 2005, our unpublished observations), indicating
that a perturbed clearance, rather than an altered expression of fibronec-
tin, is responsible for its accumulation. Selective removal of astrocyte-
derived fibronectin from the lesion site reveals that although dimeric
fibronectin promotes OPC proliferation following demyelination, reduced
numbers of OPCs suffice for successful remyelination (Stoffels, Hoekstra,
Franklin, Baron, & Zhao, 2015). Therefore, removal of dimeric or aggre-
gated fibronectin may represent a therapeutic strategy to promote
remyelination inMS.
Important players in controlled ECM degradation are matrix metal-
loproteinases (MMPs). Commonly, MMPs are synthesized and secreted
as pro-enzymes that are subsequently activated by various proteinases,
including other MMPs and plasmin (Lu, Takai, Weaver, & Werb, 2011).
Under healthy conditions, MMPs are transiently involved in the regula-
tion of ECM dynamics upon injury, and are under strict (local) control
at various levels, including gene transcription, synthesis, secretion, pro-
peptide activation, and inhibition by physiological tissue inhibitors of
MMPs (TIMPs). MMPs are implicated in the pathogenesis of MS, and
some MMPs, including MMP3, MMP7, and MMP9, are upregulated in
MS lesions (Cuzner et al., 1996; Maeda & Sobel, 1996; Cossins et al.,
1997; Anthony et al., 1997; Lindberg et al., 2001). While fibronectin is
a substrate for at least 14 distinct MMPs (Lu et al., 2011), it is unknown
whether they dissociate, cleave and/or degrade fibronectin aggregates.
Given the role of MMPs in ECM remodeling in injured CNS, we
examined here whether a perturbed expression and/or malfunctioning
of MMP3, MMP7 or MMP9 contributes to the inability to clear dimeric
fibronectin and/or fibronectin aggregates in MS lesions. We
demonstrate that MMP7 cleaved fibronectin aggregates and that
proMMP7 is weakly expressed in chronic MS lesions compared with
remyelinated lesions. IL-4-activated microglia and macrophages were
major cellular sources of proMMP7. Hence, local targeting of MMP7
levels in chronic MS lesions may represent a first step to remove
remyelination-inhibiting fibronectin aggregates.
2 | MATERIALS AND METHODS
2.1 | MS lesions
Autopsy samples of human brain material were obtained from the
Netherlands Brain Bank and with the approval of the VU University
Medical Ethical Committee (Amsterdam, The Netherlands). Patients
and controls, or their next of kin, had given informed consent for the
use of their brain tissue and clinical details for research purposes.
For immunohistochemical analysis paraffin-embedded (n 5 12) or
snap-frozen (n 5 5) tissue from MS patients and non-neurological con-
trols (n 5 3) were used. Western blot studies were performed on nine
control white matter (CWM), eight (chronic) active MS lesion [(c)aMS)],
nine chronic inactive MS lesion (ciMS), and two remyelinated MS lesion
(rMS) homogenates. Brain tissue was homogenized as previously
described (Maier et al., 2007). CWM did not show any histological signs
of inflammation and demyelination and was obtained from subjects
without clinical signs of neurological disease. MS lesions were classified
as previously described (van der Valk & De Groot, 2000).
2.2 | Toxin-induced demyelination
2.2.1 | Lysolecithin
To induce local demyelination 8–10-week-old female C57BL/6 mice
(for RT-qPCR) or Sprague Dawley rats (for Western blot) were injected
with 1 ml of 1% lysolecithin (Sigma) in spinal cord white matter (Zhao,
Li, & Franklin, 2006). At indicated time points, animals were sacrificed
and tissue processed for Western blot and qPCR analysis as previously
described (Zhao et al., 2006; Stoffels et al., 2013). For immunohisto-
chemistry, animals were perfused with 4% paraformaldehyde via the
left ventricle, after which the dissected spinal cord containing lesions
was treated with 20% sucrose in phosphate-buffered saline (PBS) over-
night. The brains were cryosectioned at 12 lm thickness and stored at
2808C until further processing. Control spinal cord tissues were taken
from non-lesioned thoracic segments of spinal cord, distant from the
lesion site. Experiments were performed in compliance with UK Home
Office regulations.
2.2.2 | Cuprizone
To induce robust and reproducible demyelination of the corpus cal-
losum, 9-week old male C57BL/6 mice (Harlan, Horst, the Netherlands)
were individually housed and subjected to a standard powder chow
diet containing 0.2% cuprizone (bis(cyclohexanone)-oxaldihydrazone,
Sigma, St. Louis, MO). After 5 weeks, animals returned to standard
chow. Tissue was processed as described for lysolecithin-induced
lesions. Demyelination of the corpus callosum was confirmed by Sudan
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black staining (0.1% in 70% ethanol for 5 min). All experimental proce-
dures were approved by the Animal Ethical Committee of the Univer-
sity Medical Center Groningen (the Netherlands).
2.3 | Primary cell cultures
2.3.1 | CNS-resident cells
Primary cultures were derived from forebrains of 1–2 day-old Wistar
rats (Charles River) as described (Bsibsi, Nomden, van Noort, & Baron,
2012). A single cell suspension was obtained by mechanical and
enzymatic (papain) digestion. Cells were cultured for 10–12 days on
poly-L-lysine (PLL, 5 mg/ml, Sigma)-coated tissue culture flasks (Nalge
Nunc, Naperville, IL). OPCs and microglia grown on top of an astrocyte
monolayer were isolated by a shake-off procedure. First, microglia were
detached by rotation on an orbital shaker (Innova 4000, New Bruns-
wick Scientific) at 150 rpm for 1 hr. Upon centrifugation for 5 min at
150g, cells were resuspended in microglia medium (DMEM [Life Tech-
nologies, Paisley, UK]; 10% fibronectin-free fetal bovine serum [FBS,
Capricorn, Ebsodorfergrund, Germany see below]; 1% antibiotics [Life
Technologies] and 1% glutamine [Life Technologies]). Microglia were
plated at a density of 2.0 3 106 cells per 10-cm dish (Corning, Lowell,
MA) and cultured with rat recombinant macrophage colony-stimulating
factor (M-CSF, 10 ng/ml, Peprotech, London, UK). After 3 days, micro-
glia were gently scraped, centrifuged for 5 min at 150g, and plated in
6-well-plates at a density of 1.0 3 106 cells per well (in 1 ml). Microglia
(>95% Iba1-positive) were left untreated, or treated with either rat
IFNg (400 ng/ml, Peprotech) and lipopolysaccharide (LPS from E.coli
O111:B4, 200 ng/ml, Sigma), or rat IL-4 (40 ng/ml, Peprotech) for 6 hr
(qPCR analysis) or 48 hr (Western blot analysis).
The mixed glia flasks were shaken overnight on the orbital shaker at
240 rpm, and the floating OPCs obtained by this procedure were further
purified via differential adhesion (Bsibsi et al., 2012). Isolated OPCs (>97%
Olig2-positive) were plated at a density of 1.0 3 106 per 10-cm dish (in
6 ml) for Western blotting or on 8-well Permanox chamber slides (Nunc)
at a density of 30,000 cells per well for the maturation assays. OPCs were
cultured for 2 days in SATO medium (Maier, Baron, & Hoekstra, 2005)
supplemented with growth factors FGF-2 (10 ng/ml, Peprotech) and
PDGF-AA (10 ng/ml, Peprotech). To obtain mature oligodendrocytes, OPC
maturation was initiated by growth factor withdrawal and culturing in
SATO supplemented with 0.5% FBS for 7 days.
To obtain astrocytes, the remaining astrocyte monolayer in the
mixed glia flasks was shaken on the orbital shaker at 240 rpm over-
night, followed by one passage to T162 flasks. At 90% confluency, the
astrocytes were trypsinized and plated in 6-well plates at a density of
0.5 3 106 cells per well (in 1 ml) in DMEM and 10% fibronectin-free
FBS (see below). Astrocytes (>97% Aldh1L1-positive) were untreated,
or treated with a pro-inflammatory cytokine cocktail containing rat
TNFa (10 ng/ml, Peprotech), rat IFNg (400 ng/ml) and rat IL1b (10 ng/ml,
Peprotech) for 6 (RT-qPCR analysis) or 48 hr (Western blot analysis).
2.3.2 | Bone marrow-derived macrophages
Macrophages were derived from the bone marrow of 1–2 day-old
Wistar rats (Charles River). The femorae and tibiae bone marrow were
flushed with BMDM medium (Roswell Park Memorial Institute [RPMI]-
1640 medium [Life Technologies]). Subsequently, all suspensions were
centrifuged for 5 min at 150g, and cell pellets were resuspended in
BMDM medium supplemented with 10% fibronectin-free FBS, 1%
sodium pyruvate (Life Technologies), and 1% antibiotics. Macrophages
(>95% isolectin-B4-positive) were plated at a density of 2.0 3 106 cells
per 10-cm dish and cultured with rat M-CSF (10 ng/ml) for 5–7 days.
For experimental analysis, macrophages were plated and treated as
described for microglia.
2.4 | Generation of fibronectin aggregates
Deoxycholate (DOC)-insoluble aggregated fibronectin was prepared
from primary rat astrocytes or MS lesions homogenates. Astrocytes
were plated at a density of 1 3 106 cells per 10-cm dish, and after 1 hr
treated with Toll-like receptor 3 agonist poly(I:C) (50 lg/ml, GE Health-
care, Munich, Germany). After 48 hr, astrocytes were removed by
water-lysis for 2 hr at 378C. The remaining astroglial matrices were
scraped into ice-cold DOC buffer (2% deoxycholate [Sigma] in 20 mM
Tris-HCl supplemented with complete Mini Protease inhibitor cocktail
[Roche, Mannheim, Germany], pH 8.0). For extraction of fibronectin
aggregates from MS lesions, tissue homogenates (100 lg) were incu-
bated in ice-cold DOC buffer for 30 min. To separate DOC-insoluble
fractions that contain fibronectin aggregates from the suspension, cen-
trifugation was performed at 16,300g for 30 min. The fibronectin
aggregate-containing pellet was washed three times in PBS, followed
by resuspension in PBS with a syringe and 25-gauge needle. The qual-
ity of the fibronectin aggregates, that is, the lack of dimeric fibronectin
and/or smaller products, and the extent of aggregation, was routinely
checked by Western blot.
2.5 | Fibronectin-free serum
Fibronectin was depleted from serum with a gelatin sepharose 4B
column (GE healthcare) according to manufacturer’s instructions. The
generated fibronectin-free serum was filtered (0.2 lm) and stored in
aliquots at 2208C. The absence of fibronectin in serum was confirmed
by Western blot.
2.6 | Fibronectin degradation assay
Plasma bovine fibronectin (5 lg, Sigma), human cellular fibronectin (5 lg,
Sigma) and rat and human fibronectin aggregates (5 lg, see above) were
respectively incubated with 100 ng recombinant human active MMP3
(Abcam, Cambridge, UK), MMP7 (Millipore, Darmstadt, Germany), and
MMP9 (Millipore, San Diego, CA) in 50 ml MMP-reaction buffer (50 mM
Tris-HCl, 0.15 M NaCl, 5 mM CaCl2, 0.05% Brij-35, pH 7.5) at 378C for
24 hr. For Western blot analysis, the reaction was terminated by adding
non-reducing SDS sample buffer. For coating purposes, the enzymatic
activity of MMP7 was terminated by heating at 958C for 10 min. Alterna-
tively, fibronectin structural variants were incubated with PBS or cell con-
ditioned media (35 ml) in the presence or absence of general MMP-
activator, 4-aminophenylmercuric acetate (APMA, 2 mM, Sigma) in 50 ll
MMP reaction buffer and incubated at 378C for 72 hr.
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2.7 | Lactate dehydrogenase and MTT assay
OPCs were cultured in 24-wells plates at a density of 50,000 cells per
well on the indicated substrates. After 48 hr the medium [lactate dehy-
drogenase (LDH) assay] and cells [3- (4,5-Dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide; MTT assay] were analyzed as described (Stoffels
et al., 2013). Briefly, the release of LDH into the medium was measured
using a commercial LDH assay kit (Roche) according to manufacturer’s
instructions. The effect on cell viability was determined with an MTT
assay, for which cells were incubated withMTT diluted in culture medium
(0.5 mg/ml, Sigma) for 4 hr. MTT-formazan crystals were collected in
dimethyl sulphoxide and absorption measured at 560 nm.
2.8 | Immunohistochemistry
2.8.1 | Toxin-induced lesions
Sections were blocked and permeabilized with PBS containing 5% normal
donkey serum and 0.1% Triton-X-100. Sections were incubatedwith amix-
ture of primary antibodies (Table 1) overnight at 48C, followed by a 2-hr
incubation with appropriate Alexa-conjugated secondary antibodies. Nuclei
were visualized by Hoechst 33342 or DAPI (1 mg/ml, Sigma). Sections were
analyzed with confocal laser scanning microscopy (Leica SP8 AOBS).
2.8.2 | MS lesions
Luxol-fast blue staining was used to identify shadow plaques. To visual-
ize myelin loss, microgliosis and (pro)MMP3 and (pro)MMP7 expres-
sion, 5-mm serial sections of active (n 5 3), chronic active (n 5 3) and
inactive lesions (n 5 3), shadow plaques (n 5 3) and healthy controls
(n 5 3) were single-stained or double-stained. Slides were
deparaffinized in xylene and descending ethanol concentrations. After
endogenous peroxidase inhibition with H2O2, antigen retrieval and/or
blocking (Table 1), sections were incubated with primary antibodies for
1 hr or overnight (Table 1). The sections were washed and incubated
with appropriate horseradish peroxidase-conjugated secondary anti-
bodies (Dako) for 1 hr and visualized with 3,3’-diaminobenzidine (DAB,
1:50, Dako, Heverlee, Belgium) for 10 min. For single staining, sections
were counterstained with haematoxylin, dehydrated in ascending con-
centrations of alcohol and xylene and mounted with Quick-D mounting
medium (Merck, Darmstadt, Germany). For double-staining, slides were
heated to detach the first primary antibody or directly incubated with
appropriate alkaline phosphatase (AP)-conjugated second primary anti-
body for 1 hr or overnight. AP-labeled cells were visualized with liquid
permanent red (Dako, 1:100) for 10 min. Sections were counterstained
with haematoxylin and mounted with Aquatex (Merck). For MMP-7
and CD40/CD206 double-staining, 5 mm cryosections containing
active MS lesions (n 5 5) were dried overnight, fixated for 10 min in
4% paraformaldehyde and incubated with 0.1% glycine for 10 min.
After blocking with H202, slides were incubated overnight with both
primary antibodies (Table 1), which were visualized with DAB and liq-
uid permanent red (LPR) as described above. Sections were analyzed
and representative pictures were taken with an Olympus BX41 micro-
scope, equipped with a Leica MC170 HD camera.
2.9 | Immunocytochemistry
Cells were fixed with 4% paraformaldehyde in PBS for 20 min, permeabil-
ized for 5 min in ice-cold methanol and blocked with 4% BSA for 30 min.
The cells were incubated for 1–2 hr with anti-MBP, followed by incubation
TABLE 1 Primary antibodies used during WB, ICC, and IHC
Company WB ICC/IHC Antigen retrieval (ICC/IHC) Blocking (ICC/IHC)
Anti-actin (mAb) Sigma 1:1000 n.a. n.a. n.a.
Anti-arginase-1 (mAb) BD Bioscience 1:250 n.a. n.a. n.a.
Anti-CD40 (mAb) AbDSerotec n.a. 1:800 no no
Anti-CD206 (mAb) BD Bioscience n.a. 1:800 no no
Anti-EIIIA-fibronectin (mAb) Sigma 1:500 n.a. n.a. n.a.
Anti-fibronectin (pAb) Millipore 1:1000 n.a. n.a. n.a.
Anti-HLA-DR (mAb) Ebioscience n.a. 1:1000 (single)
1:2000 (double)
Citrate buffer (pH 6.0) no
Anti-MBP (mAb) Serotec n.a. 1:250 no 4% BSA
Anti-MMP3 (pAb) Abcam 1:1000 n.a. Citrate buffer (pH 6.0) no
Anti-MMP7 (pAb) Gene Tex and Bioworld 1:1000 1:500 TRIS/EDTA (pH 9.0) antibody diluent with 10%
normal human serum
Anti-MMP9 (pAb) Torrey Pines Biolabs 1:1000 n.a. n.a. n.a.
Anti-iNOS (mAb)) BD Biosciences 1:500 n.a. n.a. n.a.
Anti-PLP (mAb) Bio-rad n.a. 1:3000 no no
Anti-vimentin (mAb) In house (V9) n.a. 1:6000 Citrate buffer (pH 6.0) no
n.a.5not applicable; mAb5monoclonal antibody; pAb5polyclonal antibody; WB5Western blot; ICC5 immunocytochemistry;
IHC5 immunohistochemistry.
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with an appropriate TRITC-conjugated secondary antibody (1:50, Jackson
ImmunoResearch, Westgrove, UK) and DAPI for 25 min. Cells were cov-
ered with mounting medium (Dako) to prevent image fading and analyzed
with conventional immunofluorescence microscopy (Olympus AX70 or
Leica DMI 6000 B). Oligodendrocytes were characterized by morphology,
that is, cells with typical astrocytic morphology were excluded (<3%), and
in each experiment at least 250 cells were manually scored as either MBP-
negative orMBP-positive, while in additionMBP-positive cells were classi-
fied as myelin membrane-forming or non-myelin membrane-forming.
2.10 | Western blot analysis
Cells were collected by scraping with PBS and centrifuged at 9,200g
for 5 min. Cell pellets were sonicated in TNE buffer (50 mM Tris-HCl,
150 mM NaCl, and 5 mM EDTA, pH 7.5) for 10 s on ice. Total protein
concentration was measured by a Bio-Rad DC Protein Assay (Bio-Rad
Laboratories, Herculas, CA) using BSA as standard. Equal amounts of
protein (50 lg for cell lysates and brain homogenates) or equal volumes
of medium (40 ml) were mixed with SDS-reducing loading buffer, dena-
tured at 958C for 5 min and subjected to Western blotting as previ-
ously described (Bsibsi et al., 2012). Primary antibodies used are
indicated in Table 1. The signals were detected using the Odyssey
Infrared Imaging System (LI-COR Biosciences, Lincoln, NE) and ana-
lyzed using Scion image software.
2.11 | Real-time quantitative polymerase chain
reaction reaction (RT-qPCR)
Total RNA was extracted from cells with the RNeasy Micro Kit (Qiagen,
Hamburg, Germany), according to manufacturer’s instructions. Total
RNA (1 lg) was reverse transcribed using oligo (dT)12–18 (500 lg/ml,
Invitrogen, Paisley, UK), 10 mM dNTP Mix (Invitrogen), 0.1 M dithio-
threitol (DTT, Sigma), 53 first strand buffer and Moloney Murine Leu-
kemia Virus Reverse Transcriptase (M-MLV RT, Invitrogen). RT-qPCR
was performed by an Applied Biosystems 7900HT Real-Time PCR Sys-
tem. For each reaction, 10 ng cDNA, 10 pM primers (Table 2) and abso-
lute SYBR Green Rox Mix (ThermoScientific, Breda, the Netherlands)
were mixed. Gene expression was calculated by the 2-DDct method.
GADPH and HMBS were used as housekeeping genes.
2.12 | Statistics
Data are expressed as mean 6 SEM for at least three independent
experiments. Statistical analysis was performed with a one sample
TABLE 2 Primer pair set sequences used during RT-qPCR
Forward primer Reverse primer Length (bp)
MMP2 (Rn) GCTTCTGTCCTGACCAAG CAGGGTCCTGAGAGTGTTC 90
MMP3 (Mm) TGGAGATGCTACTTTGACG AGCCTTGGCTGAGTGGTAGA 121
MMP3 (Rn) GCGGGGAGAAGTCTTGTTCT AGACGGCCAAAATGAAGAGA 100
MMP7 (Mm) TAGGCGGAGATGCTACTTT GTGGCAGCAAACAGGAAGTT 82
MMP7 (Rn) CGGAGATGCTCACTTTGACA CATGAGTGGCAACAAACAGG 83
MMP8 (Rn) TTGGACATTCCTTGGGACTC AGGTTGGACAGGGTTGTCTG 155
MMP9 (Rn) TGTATGGTCGTGGCTCTAAAC GTGGGACACATAGTGGGAG 91
MMP11 (Rn) GGCAACTTGTAAGGGAGCAG AAGTTGTCCCCATGCCAGTA 148
MMP12 (Rn) TGGTACCTTAGCCCATGCTT AGGAACAGGTTTGTGCCTTG 108
MMP13 (Rn) GCCAGAACTTCCCAACCA CCGCAGCACTGAGCCTT 176
MMP14 (Rn) AATAAGTACTACCGCTTCATG GAGACTCAGGGATTCCTTC 91
ADAMTS4 (Rn) GCCCGATTCATCACTGACTT GCGGTCAGCATCATAGTCCT 117
TIMP1 (Mm) TCCCCAGAAATCAACGAGAC CATTTCCCACAGCCTTGAAT 88
TIMP1 (Rn) GGTTCCCTGGCATAATCTGA ATGGCTGAACAGGGAAACAC 99
TIMP2 (Rn) TGGACGTTGGAGGAAAGAAG TCCCAGGGCACAATAAAGTC 97
TIMP3 (Rn) GACCACAGCAGCTACCATGA GCTTCTTTCCCACCACTTTG 167
TIMP4 (Rn) TGCCAAATCACCACTTGCTA ATAGAGCTTCCGTTCCAGCA 93
tPA (Rn) ACGTACAGCTCCCTGACTGG CAGCCGGTCAGAGAAGAAAG 86
uPA (Rn) TGCCCAAAGAAATTCAAAGG CGGCCTTTGGTGTCAGTATT 110
HBMS (Mm/Rn) CCGAGCCAAGCACCAGGAT CTCCTTCCAGGTGCCTCAGA 107
GAPDH (Mm/Rn) CATCAAGAAGGTGGTGAAGC ACCACCCTGTTGCTGTAG 204
Mm5mus muculus; Rn5 rattus norvegicus; RT-qPCR5 real-time quantitative analysis.
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t test when relative values of conditions were calculated by setting the
control as 1 in each independent experiment. When absolute values of
two means were compared, statistical significance was calculated by
Student’s t test, and when more than two means were compared, by
one-way analysis of variance (ANOVA), followed by Newman-Keuls
multiple comparison test post-test. In all cases, p < .05 was considered
significant.
3 | RESULTS
3.1 | proMMP3 and MMP7 are upregulated upon
toxin-induced demyelination
Immunohistochemical analysis and in situ hybridization studies revealed
that expression of fibronectin-degrading proteinases MMP3 and
MMP7 is enhanced in active demyelinating MS lesions (Anthony et al.,
1997; Cossins et al., 1997; Lindberg et al., 2001). To examine whether
the enhanced expression of these MMPs in MS lesions is a natural
response to a demyelinating insult, we first examined their expression
levels in two different animal models of toxin-induced demyelination.
Notably, we and others have previously shown that upon toxin-
induced demyelination, dimeric fibronectin is transiently increased dur-
ing demyelination, and its clearance commensurate with remyelination
(Zhao et al., 2009; Hibbits et al., 2012; Stoffels et al., 2013; Espitia Pin-
zon et al., 2017), making it an ideal model to examine the regulation of
“natural” fibronectin-degrading proteolytic enzymes involved in ECM
remodeling upon CNS demyelination. Focal demyelination in spinal
cord white matter is induced by a single injection of the detergent lyso-
lecithin, being maximal at 5 days post lesion (DPL), which is followed
by robust remyelination at 14–21 DPL (Zhao et al., 2006). As shown in
Figure 1a, upon lysolecithin-induced demyelination MMP7 mRNA le-
vels were increased at demyelination (3 and 5 DPL), while both MMP3
and MMP7 mRNA levels were significantly enhanced at remyelination
(14 DPL). Coincidentally, mRNA levels of TIMP1, a natural inhibitor of
MMPs, were substantially increased at demyelination, and decreased at
remyelination (14 DPL) compared with 5 DPL (Figure 1a). This indicates
that MMP3 and MMP7 may exhibit higher activity at 14 DPL. Western
blot (Figure 1b,d) and immunohistochemical (Figure 1e) analyses con-
firmed the increased expression of MMP7 protein at remyelination (14
DPL) compared with demyelination (5 DPL). A clear shift from
proMMP7 to MMP7 was observed at remyelination (Figure 1b,d), and
double staining with the microglia/macrophage marker Iba1 demon-
strated that (pro)MMP7 is present in microglia/macrophages (Figure
1e, arrow), as well as extracellularly, which may represent secreted
(pro)MMP7. The increased level of MMP3 mRNA was not reflected by
an increased protein level of proMMP3 and MMP3 at 5 and 14 DPL
(Figure 1b,c). Next, the expression of MMP3 and MMP7 upon
cuprizone-induced demyelination was examined. Feeding animals with
the copper-chelator cuprizone for several weeks induces reproducible
demyelination of the corpus callosum, while withdrawal of cuprizone is
followed by remyelination (Gudi, Gingele, Skripuletz, & Stangel, 2014).
Upon 3 and 5 weeks of cuprizone treatment, demyelinated areas were
readily visible in the corpus callosum, while remyelination, as reflected
by the reappearance of Sudan Black staining, occurs 2 weeks after
cuprizone removal (Figure 2a). Western blot analysis of total corpus cal-
losum homogenates demonstrated increased proMMP3 levels during
remyelination compared with control and demyelinating conditions
(Figure 2b,c), consistent with previous reports (Ulrich et al., 2006;
Skuljec et al., 2011). Also, (pro)MMP7 and MMP7 were present during
demyelination and remyelination, while in contrast to lysolecithin-
induced demyelination, no difference in their ratio was observed (Fig-
ure 2b,d). Immunohistochemical analysis confirmed the similar (pro)
MMP7 expression levels (Supporting Information Figure S1). In contrast
to lysolecithin-induced lesions, (pro)MMP7 was scarcely localized to
Iba1-positive microglia/macrophages and appears to localize extracellu-
larly (Supporting Information Figure S1, insets), while a prominent
increase in Iba1-positive microglia/macrophages was evident at 3 and
5 weeks demyelination. This discrepancy may be explained by taking
into account that in the lysolecithin-induced lesions (pro)MMP7 levels
were examined during early remyelination, whereas in the cuprizone
model (pro)MMP7 levels were analyzed at conditions at which remyeli-
nation nears completion. This suggests that microglia/macrophages
transiently express MMP7, and therefore, the presence of (pro)MMP7
during remyelination upon cuprizone-induced demyelination may be
underestimated. Hence, these findings show that (pro)MMP3 and (pro)
MMP7 are present in demyelinated areas, and that their expression
levels are enhanced during the remyelination process, indicating that
they may be involved in ECM remodeling upon injury, including fibro-
nectin clearance, which we examined next.
3.2 | MMP7 cleaves fibronectin aggregates into a
13 kDa EIIIA (rat)/16 kDa EDA (human)-containing
fragment
Both plasma and cellular fibronectin are assembled into fibronectin
aggregates (Stoffels et al., 2013). Therefore, to examine the ability of
MMPs to digest fibronectin, we incubated different fibronectin
structural variants, including fibronectin aggregates, with active
human recombinant MMP3, MMP7, and MMP9. When plasma
(bovine) and cellular (human) fibronectin were incubated with
recombinant MMP7, the protein was degraded, and multiple frag-
ments, as detected by Western blot analysis (Figure 3a), were
obtained after 24-hr incubation. Intriguingly, the molecular weight
(Mw) of the generated fibronectin fragments obtained with the dis-
tinct structural variants recognized by a polyclonal anti-fibronectin
antibody, differed. MMP7-mediated degradation of plasma fibronec-
tin generated 6 prominent fragments with a Mw between 154 and
82 kDa, and a fragment with an apparent Mw of 23.5 kDa, while
MMP7-mediated cleavage of cellular fibronectin resulted in frag-
ments of 110, 60 and 28 kDa (Figure 3a, arrows). MMP3 and MMP9
were less efficient in the degradation of dimeric plasma and cellular
fibronectin within the 24-hr time frame. Although MMPs and fibro-
nectin are well-conserved among species and while human cellular
fibronectin is also not degraded, it cannot be excluded that the lack
of bovine plasma fibronectin degradation by MMP3 and MMP9 is
due to species differences. When aggregated fibronectin was
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incubated with the recombinant MMPs, an 9 kDa fragment
appeared as major product following incubation with MMP7, but not
with MMP3 and MMP9. Silver staining showed a similar degradation
profile of the MMPs, as well as additional bands apart from the
recombinant MMPs themselves (data not shown). Fibronectin aggre-
gates were obtained from poly(I:C)-stimulated astrocytes and
FIGURE 1 MMP expression upon lysolecithin-induced demyelination. (a) Real-time quantitative PCR analysis of (pro)MMP3, (pro)MMP7 and TIMP1
against GAPDH (shown) and HMBS (not shown, but yielding comparable findings) in non-lesioned spinal cord white matter and lysolecithin-induced lesions.
DPL is days post lesion. Bars depict relative mean expression levels1 SEM versus 1 control animal which was set at 1. Statistical differences as assessed with
a one-way ANOVA (comparedwith ctrl **p< .01, ***p< .001; comparedwith 14DPL ##p< .01, Newman-Keuls, n 3). (b)Western blot showing (pro)
MMP3 and (pro)MMP7 expression in non-lesioned and lysolecithin-induced lesions (50 mg). Actin serves as a loading control. Representative blots of three
animals per condition are shown. (c and d) Quantitative analysis of proMMP3 and 35 and 50 kDaMMP3 (c) and proMMP7,MMP7, andMMP7/
proMMP71MMP7 (d) expression of b. Bars depict mean1 SEM of the relativeMMP expression to actin. Statistical differences as assessedwith a one-way
ANOVA are indicated (*p< .05, Newman-Keuls, n5 3). (e) Double staining of non-lesioned and lysolecithin-induced lesions forMMP7 (red) and themicroglia
marker Iba1 (green). Hoechst-stained nuclei are indicated in blue. Scale bars are 100 or 20 lm (insets) [Color figure can be viewed at wileyonlinelibrary.com]
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consists of both bovine plasma and rat cellular fibronectin. Plasma
and cellular fibronectin are distinguished by the sole presence of
extradomain EIIIA and/or extradomain EIIIB (EDA and EDB in human)
in cellular fibronectin (Paul, Schwarzbauer, Tamkun, & Hynes, 1986).
To visualize cellular fibronectin-derived degradation products, the
degradation fragments of cellular and aggregated fibronectin were
analyzed with a monoclonal antibody that specifically recognizes the
EIIIA/EDA domain. A fragment with an apparent Mw of 13 kDa was
clearly visible upon MMP7-mediated degradation of aggregated
fibronectin (Figure 3b), which is similar to the predicted Mw of the
full EIIIA domain (Shinde et al., 2008). This suggests that MMP7-
catalyzed cleavage of aggregated fibronectin involves the release of
the EIIIA domain. MMP7-mediated cleavage of human cellular fibro-
nectin generated three major degradation products of approx. 102,
59, and 16 kDa. The 16-kDa product is likely the EDA domain, that
is, the human equivalent of the EIIIA domain (Stine, Sun, Armstrong,
Bowler, & Briknarova, 2015). To assess whether MMP7 is able to
degrade MS lesion-derived fibronectin aggregates, aggregates
obtained from three chronic active and three chronic inactive MS
lesions from different patients were incubated with recombinant
MMP7. Using the anti-EIIIA/EDA-fibronectin antibody, a 16-kDa
degradation product was visible, which is likely the human equivalent
of the 13-kDa EIIIA-containing fragment, generated from rat-derived
astrocytes (Figure 3c). In contrast to rat-derived astrocytes, signifi-
cant quantities of intact aggregates exist, indicating that MS lesion-
derived aggregates are more stable or reflecting a limited MMP7-
induced cleavage. Together, the data demonstrate that recombinant
MMP7 catalysed the cleavage of fibronectin aggregates into a small
EIIIA/EDA-domain containing fragment.
3.3 | MMP7-cleaved fibronectin aggregate coatings
inhibit OPC maturation
To assess whether the MMP7-mediated proteolytic digestion of fibro-
nectin aggregates is sufficient to overcome the aggregated
fibronectin-mediated inhibition of myelin membrane formation, OPCs
were plated on intact fibronectin aggregates or aggregates that were
cleaved with recombinant MMP7 (see Figure 3). As shown in Figure 4,
MMP7-cleaved fibronectin aggregate coatings inhibited OPC differen-
tiation as reflected by a decrease in the percentage of MBP-positive
cells compared with cells grown on PLL. In fact, on MMP7-cleaved
fibronectin aggregate coatings the percentage of MBP-positive cells
was reduced compared with cells that were cultured on intact fibro-
nectin aggregates (Figure 4a,c). Consistent with previous findings (But-
tery & ffrench-Constant, 1999, Siskova et al., 2007, 2009, Stoffels
et al., 2013), oligodendrocytes plated on fibronectin structural variants
are morphologically immature compared with oligodendrocytes plated
on PLL (Figure 4b). Similar experiments with MMP7-cleaved plasma
and cellular fibronectin coatings revealed an augmented inhibition of
OPC differentiation when plated on MMP7-cleaved fragments com-
pared with intact fibronectin (Figure 4c). Notably, coatings of the
cleaved fibronectin fragments did not contain MMP7 (data not
shown), indicating that MMP7 is washed away upon coating and that
a potential carry-over effect of MMP7 can be excluded. This indicates,
that fibronectin fragments, either plasma or cellular fibronectin-
derived, more prominently decreased OPC differentiation compared
with intact fibronectin. In addition, intact fibronectin aggregate, and to
a lesser extent cellular fibronectin, but not plasma fibronectin coatings,
inhibited OPC differentiation compared with PLL (Figure 4c). We have
FIGURE 2 MMP expression upon cuprizone-induced demyelination. (a) Sudan Black staining of control mice (ctrl), mice fed with 0.2%
cuprizone for 3 or 5 weeks (3 or 5 wks DM), and mice 2 weeks after removal of 5 weeks cuprizone feeding (2 wks RM). Note the absence
of Sudan Black staining, indicating prominent demyelination (DM), at the corpus callosum at 3 and 5 weeks, and the reappearance of Sudan
Black staining, that is, remyelination (RM), upon 2 weeks of cuprizone removal. Scale bar is 200 mm. (b) Western blot showing (pro)MMP3
and (pro)MMP7 expression in total corpus callosum homogenates (50 mg) of mice indicated in a. Actin serves as a loading control. Represen-
tative blots of four animals per condition are shown. (c and d) Quantitative analysis of proMMP3 and MMP3 (c) and proMMP7, MMP7, and
MMP7/proMMP71MMP7 (d) expression of b. Bars depict mean 1 SEM. Statistical differences as assessed with a one-way ANOVA
(*p < .05, Newman-Keuls)
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previously shown that aggregated fibronectin is not toxic to oligoden-
drocytes (Stoffels et al., 2013). To exclude that MMP7-cleaved fibro-
nectin fragments were toxic and/or affected the viability of cells, we
performed LDH and MTT assays. Coatings of MMP7-cleaved cellular
fibronectin and aggregated fibronectin fragments scarcely affected the
release of LDH (Figure 4e) or levels of MTT reduction (Figure 4f)
compared with their intact counterparts, while MMP7-cleaved plasma
fibronectin coatings were slightly toxic. However, the concomitant
increase rather than decrease in MTT reduction, suggests an increase
in the number of cells on an MMP7-cleaved plasma fibronectin coat-
ing, which is likely due to an increase in OPC proliferation rather than
cell death. MMP7-cleaved fibronectin aggregate, cellular fibronectin
FIGURE 3 Degradation of fibronectin structural variants by recombinant MMPs. (a and b) Bovine plasma fibronectin (pFn, 5 mg), human
cellular fibronectin (cFn, 5 mg) and aggregated rat fibronectin (aFn, 5 mg) were incubated with vehicle (PBS, 2), or recombinant human
MMP3, MMP7, or MMP9 for 24 hr at 378C and subjected to Western blotting (non-reducing) using a polyclonal anti-Fn antibody (a, total
Fn) or an antibody directed against the EIIIA domain of cFn (b, EIIIA/EDA-Fn). Representative blots of three independent experiments are
shown. Note that MMP7 efficiently degrades pFn, cFn, and aFn, while different Mw degradation products of either structural variant are
obtained. (c) MMP7-mediated degradation of human fibronectin aggregates obtained from 100 mg of three distinct chronic active and
chronic inactive MS lesions of three different MS patients as assessed with Western blot (non-reducing, anti-EIIIA Fn antibody). Arrow
indicates main fibronectin degradation products
WANG ET AL. | 9
and plasma fibronectin coatings inhibited myelin membrane formation
compared with PLL to a similar extent as their intact counterparts, as
indicated with the similar percentage of cells that extended MBP-
positive myelin membranes of total MBP positive cells (Figure 4d).
Hence, MMP7-mediated cleavage of fibronectin (aggregates) is a first
step to remove fibronectin (aggregates), but as the remaining degrada-
tion products inhibit OPC differentiation, further clearance by, for
example, astrocytes, microglia or macrophage-mediated phagocytosis
and/or other proteases is required.
3.4 | Levels of proMMP7 are reduced in chronic
active and chronic active MS lesions
Although enhanced presence of MMP7 in active demyelinating MS
lesions is well documented (Anthony et al., 1997; Cossins et al., 1997;
Lindberg et al. 2001), the persistence of fibronectin (aggregates) in
chronic MS lesions suggests that the inability to clear fibronectin is due
to the lack of expression and/or impairment of its activity. Therefore, we
next analyzed the presence of MMP7 in post-mortem MS and control
FIGURE 4 OPC maturation on MMP7-cleaved plasma fibronectin, cellular fibronectin and fibronectin aggregates. Oligodendrocyte progeni-
tor cells (OPCs) were differentiated on poly-L-lysine (PLL), intact plasma fibronectin (pFn), cellular fibronectin (cFn), fibronectin aggregates
(aFn) or MMP7-degraded plasma fibronectin (pFn-MMP7), cellular Fn (cFn1MMP7) or fibronectin aggregates (aFn-MMP7) for 6 days. The
experiments on the structural variants are performed in independent experiments, while PLL is used as a positive control in each experi-
ment. (a and b) Representative overview (a) and single cell (b) images of MBP immunocytochemistry (red) of oligodendrocytes (OLGs, 6 days
in differentiation) cultured on the indicates substrates. DAPI-stained nuclei are indicated in blue. Scale bar are 75 lm (a) and 10 lm (b). (c
and d) The percentage of MBP-positive cells (c) and the percentage of MBP-positive cells bearing myelin membranes (d) were assessed
6 days after initiating differentiation. Bars depict mean 1 SEM of at least five independent experiments. In each experiment, the data of
cells cultured on PLL was set at 100% (horizontal line). The percentages of MBP-positive cells or myelin membranes in cells cultured on PLL
were respectively 33.6.8% 6 9.5% and 24.0% 6 10.2% for the pFn-related experiments, 34.9.8% 6 8.6% and 26.1% 6 8.2% for the cFn-
related experiments, and 43.8% 6 11.9% and 29.1% 6 8.7% for the aFn-related experiments. Statistical differences with cells cultured on
PLL (one sample t test, ***p < .001, n 5 5) and intact fibronectin (Student’s t test, ##p < .01) are indicated. Note, that MMP7-cleaved
plasma, cellular and aggregated fibronectin inhibited OPC differentiation compared with their intact counterparts. (e and f) Cytotoxicity (e,
LDH release in culture medium) and cell viability (f, MTT reduction) assays of OPCs cultured for 2 days at the indicated substrates. Bars
depict mean 1 SEM of four independent experiments. In each experiment, the data of respective intact substrates was set at 100% (hori-
zontal line). Statistical analyses were performed using the one-sample t test when compared with the intact substrate (not significant) [Color
figure can be viewed at wileyonlinelibrary.com]
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tissue. Of note, the anti-MMP7 antibody does not distinguish proMMP7
fromMMP7 (Figures 1b and 2b). In control tissue, (pro)MMP7 is diffusely
expressed throughout the white matter (Figure 5a). In active MS lesions,
characterized by HLA-DR-expressing microglia/macrophages in the
demyelinated area (Figure 5a, van der Valk & De Groot, 2000), (pro)
MMP7 localized to HLA-DR-positive microglia/macrophages (Figure 5a,
arrow), corroborating previous studies (Anthony et al., 1997; Cossins
et al., 1997). Co-stainings of MMP7 with human phenotype-specific dif-
ferentially-activated microglia/macrophages markers (Peferoen et al.,
2015) in active MS lesions showed that (pro)MMP7 was not restricted to
and only occasionally present in both classical CD40-positive and pro-
regenerative CD206-positive microglia/macrophages (Supporting Infor-
mation Figure S2a,b). In chronic active MS lesions, characterised by a
hypocellular lesion centre and a rim of HLA-DR-positive microglia/macro-
phages (Figure 5a), (pro)MMP7 is less abundantly expressed in the rim
and lesion center compared with active lesions. In addition, (pro)MMP7 is
occasionally present in cells with an astrocyte-like morphology (Figure 5a,
arrowhead). This occasional presence of (pro)MMP7 in astrocytes was
confirmed by double labeling with the activated astrocyte marker vimen-
tin (Supporting Information Figure S2c). In chronic inactive MS lesions,
which lack HLA-DR-positive microglia/macrophages, (pro)MMP7 immu-
noreactivity is absent or only weakly expressed. Remarkably, in remyeli-
nated MS lesions, identified as a myelinated area with a less intense LFB
staining (Figure 5a), HLA-DR-positive macrophages harbor (pro)MMP7
immunoreactivity, while also a more diffuse immunoreactivity of (pro)
MMP7 as in CWM was observed. To confirm this differential expression,
we next analyzed MMP7 expression levels in chronic active and chronic
inactive MS lesions homogenates, previously shown to contain fibronec-
tin aggregates (Stoffels et al., 2013) by Western blotting. While present
in CWM and remyelinated lesions, proMMP7 levels were significantly
reduced in homogenates of chronic active and inactive MS lesions (Figure
5b,d). In contrast, proMMP3, in its active form known to be an activator
of MMP7 (Imai et al., 1995), was slightly increased in chronic active MS
lesion homogenates compared with CWM and chronic inactive MS lesion
homogenates (Figure 5b,c). Immunohistochemical analysis revealed that
(pro)MMP3 was only occasionally present in HLA-DR-positive microglia/
macrophages in active and remyelinated MS lesions, whereas (pro)MMP3
was prominently present in vimentin-positive astrocytes (Figure 5e).
Hence, these findings indicate that the absence of sufficient levels of
(pro)MMP7 in chronic active and inactive MS lesions correlates to the
persistent presence of fibronectin (aggregates). The decreased (pro)
MMP7 expression in chronic MS lesions may be a result of inappropriate
or impaired activation of cells that produce MMP7 upon myelin injury.
Therefore, we next examined in vitro which type(s) of resident cells, pres-
ent in MS lesions, is (are) the major source(s) of these MMPs.
3.5 | IL-4-activated microglia and macrophages are a
major cellular source of secreted proMMP7
Several in vitro and in vivo studies reveal that resident microglia and astro-
cytes, as well as infiltrating macrophages produce MMPs (Anthony et al.,
1997; Cossins et al., 1997; Skuljec et al., 2011). To identify cellular sour-
ces of (pro)MMP7 expression and release, and to explain its impaired
expression in chronic MS lesions, we examined the presence MMP7 in
lysates and in conditioned medium of cultured microglia and astrocytes,
as well as bone marrow-derived macrophages (referred to as “macro-
phages”) under resting (control) and/or MS-relevant conditions that do
not affect cell viability. In addition, given their role in MS pathology and/
or their ability to activate MMP7, we also examined cellular sources of
(pro)MMP3 and (pro)MMP9. Models of microglia and macrophage activa-
tion are often simplified to classical activation, evoked by exposure to
IFNg and LPS, or alternative activation, generated by exposure to IL-4.
These phenotypes are regarded as the two extremes of a continuum of
microglia/macrophage activation states (Wolf, Boddeke, & Kettenmann,
2017; Murray, 2017). As shown in Figure 6a–c, the expression levels of
proMMP3 and proMMP7 in cell lysates of IFNg1LPS-activated and IL-4-
activated microglia were similar, while proMMP7 and proMMP9 levels
were enhanced in conditioned medium of IL-4-activated compared with
IFNg1LPS-activated and non-stimulated control microglia. ProMMP3
was not detectable in conditioned microglia medium (data not shown). IL-
4-activated macrophages showed a significant increase in proMMP7 lev-
els, while proMMP3 levels were similar at all conditions (Figure 6d–f). As
in microglia, proMMP9 was weakly detectable in lysates of macrophages.
Similar to microglia, proMMP7 and proMMP9 levels were increased in
conditioned medium of IL-4-activated macrophages (Figure 6d,f),
whereas proMMP3 was hardly detectable (data not shown). Both (active)
MMP7 and MMP9 were hardly present in microglia and macrophages
lysates and conditioned medium. Importantly, consistent with the corre-
sponding phenotype, iNOS expression was increased upon exposure to
IFNg1LPS, and arginase-1, a marker for alternative activated microglia
and macrophages, was expressed upon IL-4 treatment (Figure 6a,d). Pro-
inflammatory-activated astrocytes, a condition that is relevant to MS
lesions (Nair, Frederick, & Miller, 2008; Sofroniew & Vinters, 2010),
showed increased levels of MMP7, but not proMMP3 and proMMP7
compared with control astrocytes (Supporting Information Figure S3).
ProMMP7 and proMMP9, but not MMP7, were detected in pro-
inflammatory-activated astrocyte conditioned medium, while the MMPs
were virtually absent in conditioned medium of control astrocytes (Sup-
porting Information Figure S3). While OPCs are present in most MS
lesions, their differentiation seems to be inhibited (Lucchinetti et al.,
1999, Kuhlmann et al., 2008, Chang et al., 2012), which may account for
the observed alterations in MMP expression levels. Upon differentiation
of OPCs to myelinating oligodendrocytes, proMMP3 expression signifi-
cantly increased, while proMMP7 and proMMP9 were hardly detected at
either differentiation stage (Supporting Information Figure S3). ProMMP3
was virtually absent in conditioned medium of primary oligodendrocyte
cultures (data not shown). Hence, pro-inflammatory cytokine-activated
astrocytes, and IL-4-activated microglia and macrophages secrete
proMMP7 levels that may potentially degrade fibronectin aggregates.
3.6 | MMP-activated conditioned medium of IL-4-
activated microglia and macrophages cleaves
fibronectin aggregates
As IL-4-activated microglia, macrophages, and cytokine-activated astro-
cytes secreted significant proMMP7 levels, we next determined
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whether MMPs present in the conditioned medium of either cell type
were sufficient to cleave aggregated fibronectin. Incubation with aggre-
gated fibronectin for 72 hr at 378C showed that conditioned medium
of either cell type was insufficient in cleaving aggregated fibronectin
(Figure 7). As Western blot analysis revealed that MMP7 was present
as proenzyme (Figure 6), we treated the conditioned medium with
APMA, a general activator of MMPs. Interestingly, APMA-treated, that
is, MMP-activated, conditioned medium from IL-4-activated
FIGURE 5.
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macrophages, and to a lesser extent microglia cleaved aggregated fibro-
nectin (Figure 7a,b). In IL-4-activated macrophages and microglia, simi-
lar to recombinant MMP7-mediated cleavage of aggregated
fibronectin, a major degradation product visualized with the anti-EIIIA
fibronectin antibody was a 13 kDa fragment (Figure 7b cf Figure 3b).
Also, the 9 kDa product that appears upon recombinant MMP7-
cleavage of aggregated fibronectin using the polyclonal fibronectin
antibody was visible (Figure 7a cf Figure 3a), indicating that MMP7
present in macrophage-conditioned medium likely cleaved the aggre-
gated fibronectin. In addition, and in contrast to cleavage with recombi-
nant MMP7, prominent fragments at 164, 103, 88, and 32 kDa were
visualized with the polyclonal anti-fibronectin antibody. This may relate
to the presence of macrophage-secreted fibronectin in the conditioned
medium. Macrophages and astrocytes, and to a lesser extent microglia
secreted pronounced levels of fibronectin (Supporting Information Fig-
ure S4). However, these fragments and the 13 kDa fragment were not
detected upon MMP-activation (APMA) of conditioned medium only
(Supporting Information Figure S4), indicating that these degradation
fragments were derived from aggregated fibronectin and not from cel-
lular fibronectin. Of note, conditioned medium was made with plasma
fibronectin-free serum. Complete MMP-mediated degradation of the
aggregates was not observed indicating that cleavage of aggregated
fibronectin with IL-4-activated macrophage conditioned medium was
less efficient than recombinant MMP7. Notably, with the polyclonal
anti-fibronectin antibody different fibronectin degradation products
(160 and 151 kDa) were visualized with IL-4-activated microglia-condi-
tioned medium but not in IL-4-activated macrophage-conditioned
medium (Figure 7a). To examine whether fibronectin-degrading pro-
teinases other than MMP7 and MMP9, for example, other metallopro-
teinases (MMPs, ADAMTS) and serine proteinases (plasmin), were
expressed and potentially secreted by these cells and that may explain
the difference with the recombinant MMP7-degradation profile, a com-
prehensive RT-qPCR analyses was performed. In addition, the mRNA
levels of TIMPs, which are natural inhibitors of MMPs, were deter-
mined. As shown in Table 3, MMP3, MMP13, ADAMST4 (only macro-
phages) and TIMP1 (only macrophages) were enhanced in IFNg1LPS-
activated microglia and/or macrophages, and consistent with the West-
ern blot data (Figure 6) only MMP7 mRNA was enhanced upon IL-4
treatment. This further supports the likelihood of MMP7 being
secreted by IL-4-activated microglia and macrophages that cleaved
aggregated fibronectin.
Upon MMP-activating conditions, conditioned medium of
cytokine-activated astrocytes, known to contain proMMP7 and
proMMP9 (Supporting Information Figure S3), was not able to frag-
ment aggregated fibronectin (Figure 7a,b). This indicates that other fac-
tors present in astrocyte-conditioned medium may prevent MMP7-
mediated cleavage, or that expression levels of MMPs are too low.
Expression profiling showed that upon pro-inflammatory cytokine
exposure, next to transcripts of MMP3, MMP7, MMP9, MMP12,
MMP13, and ADAMST, also the natural inhibitors of MMPs, TIMP1,
and TIMP3, were increased compared with “resting” astrocytes (Table
3). Hence, macrophages and microglia are potential cellular sources to
degrade fibronectin aggregates, and once secreted by IL-4-activated
microglia/macrophages, MMPs, most likely MMP7, require an appropri-
ate, extracellular activation, for example by other cellular sources, to
cleave aggregated fibronectin.
4 | DISCUSSION
Fibronectin aggregates present in chronic MS lesions impair OPC matu-
ration, and contribute to remyelination failure (Stoffels et al., 2013).
Here, we demonstrated that MMP7, cleaved aggregated fibronectin,
releasing an EIIIA/EDA-containing 13 (rat)/16 (human) kDa fragment.
ProMMP7 levels were reduced in chronic active and chronic inactive
MS lesions compared with control white matter and remyelinated MS
lesions, which may explain the persistence of fibronectin aggregates in
demyelinated MS lesions. Alternative (IL-4-)activated microglia and
macrophages expressed and secreted proMMP7, and cleaved fibronec-
tin aggregates in vitro at proper MMP-activating conditions. Hence,
given that microglia/macrophage activation is perturbed in MS lesions
(Vogel et al., 2013; Peferoen et al., 2015), upregulation of local MMP7
expression levels, for example by priming microglia/macrophages
towards the alternative activated phenotype, may be an attractive
approach to locally provoke degradation of fibronectin (aggregates) and
thus promote remyelination in MS.
FIGURE 5 MMP protein localization and expression in control white matter and MS lesions. (a) Serial cryosections of post-mortem control
white matter (n 5 3), active MS lesions (n 5 3), chronic active MS lesions (n 5 3), chronic inactive MS lesions (n 5 3) and remyelinated MS
(n 5 3) lesions of distinct MS patients were stained for PLP or luxol fast blue (LFB), and MHC II (HLA-DR), and double-stained for HLA-DR
and MMP7. Lesion activity was characterized by HLA-DR and PLP expression; remyelinated lesions were characterized by LFB. Arrow indi-
cates a HLA-DR and MMP7 positive microglia/macrophage; arrowhead indicates a cell that morphologically resembles astrocytes. Scale bars
are 20 (double stainings) or 200 lm (single staining). Note that in active and remyelinated MS lesions MMP7 is clearly present in microglia/
macrophages. (b) Protein levels of (pro)MMP3 and (pro)MMP7 in brain white matter homogenates (50 mg) of human control white matter
(CWM, n 5 9), (chronic) active [(c)aMS, n 5 8], chronic inactive (ciMS, n 5 9) and remyelinated (rMS, n 5 2) MS lesions as determined by
Western blotting. Demyelination was confirmed by the decreased MBP expression. Actin serves as loading control. (c and d) Quantification
of proMMP3 (c) and proMMP7 (d). Statistical differences were assessed with a one-way ANOVA (*p < .05, Newman-Keuls, n  8). Note
the decreased levels of proMMP7 in MS lesions compared with CWM, and the slight increase of proMMP3 expression in (chronic) active
MS lesions. (e) Serial cryosections of (a) double-stained for HLA-DR and MMP3 or vimentin (astrocyte marker) and MMP3. Arrow indicates
a HLA-DR-positive and (pro)MMP3-negative microglia/macrophage; arrowhead indicates a cell that morphologically resembles astrocytes.
Note the prominent presence of (pro)MMP3 in vimentin-positive astrocytes in (chronic) active lesions. Scale bars are 20 lm [Color figure
can be viewed at wileyonlinelibrary.com]
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Immunohistochemistry and in situ hybridization have shown that
several fibronectin-degrading MMPs, including MMP3, MMP7, and
MMP9 are upregulated in active demyelinating lesions (Maeda & Sobel,
1996; Anthony et al., 1997; Cossins et al., 1997; Lindberg et al., 2001).
These MMPs are present at the rim of active lesions, and less so or
confined to perivascular cuffs, in chronic MS lesions (Maeda & Sobel,
1996; Lindberg et al., 2001). The upregulated MMPs are likely part of
the neuroinflammatory response that also encompasses disruption of
the blood–brain barrier, allowing entry of blood-derived cells (Rosen-
berg, Estrada, Dencoff, & Stetler-Stevenson, 1995; Buhler et al., 2009).
However, MMPs also have beneficial roles for remyelination, including
ECM remodeling, degradation of myelin debris, and regulation of out-
growth of oligodendrocyte processes (Chandler et al., 1995; Oh et al.,
1999; Rosenberg, 2002b; Larsen & Yong, 2004; Siskova et al., 2009).
Our present findings show that MMP7 cleaved fibronectin aggregates
into small, EIIIA/EDA containing fragments. Previous studies revealed
that MMP7 is present in macrophages in active demyelinating lesions
(Anthony et al., 1997; Cossins et al., 1997). Our findings confirmed the
presence of (pro)MMP7 in activated microglia/macrophages in active
MS lesions, and in addition immunohistochemical and Western blot
analysis revealed that MMP7 expression was reduced in chronic active
and inactive lesions, that is, where fibronectin aggregates are promi-
nently present, compared with control white matter and remyelinated
MS lesions. In contrast, MMP3, known to activate MMP7, was
increased in chronic active MS lesions and prominently present in
astrocytes. Therefore, the inability to clear fibronectin aggregates in
chronic MS lesions is likely attributed to the lack of an appropriate pro-
tease, for example, MMP7, rather than to the inability to clear dimeric
fibronectin. Whether MMP7 degrades fibronectin aggregates in vivo
remains to be determined.
MMP7 is the smallest MMP, and is particularly upregulated upon
neuroinflammation in microglia/macrophages, that is in active demyeli-
nating MS lesions, and in EAE, an animal model of MS (Anthony et al.,
1997; Clements et al., 1997; Cossins et al., 1997; Kieseier et al., 1998;
FIGURE 6 MMP expression in microglia and bone-marrow derived macrophages. (a–c) Protein levels of (pro)MMP3, (pro)MMP7, and (pro)
MMP9 in control, IFNg1LPS-activated and IL-4-activated microglia in total cell lysates (50 mg) and cell-conditioned medium (CM, 40 ml) as
determined by Western blot. Representative blots of three to eight independent experiments (a), quantitative analysis of proMMP3 and
proMMP7 in cell lysates (b), and proMMP7 and proMMP9 levels in medium (c). Actin serves as a loading control. (d–f) Protein levels of
MMP3, MMP7, and MMP9 in control, IFNg1LPS-activated and IL-4-activated bone marrow-derived macrophages in total cell lysates
(50 mg) and cell-conditioned medium (CM, 40 ml) as determined by Western blot. Representative blots of six to fifteen independent experi-
ments (d), quantitative analysis of proMMP3 and proMMP7 in cell lysates (e), and proMMP7 and proMMP9 levels in medium (f) are shown.
Actin serves as a loading control. Bars depict mean 1 SEM relative to control. Statistical differences as assessed with a one-sample t test
are indicated (*p < .05, n  4)
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Lindberg et al., 2001). MMP7 is implicated in blood–brain barrier dis-
ruption, axonal injury and is involved in shedding of signaling mole-
cules, including TNF, that contribute to the pathology of MS (Chandler
et al., 1995; Gearing et al., 1995; Kieseier et al., 1998; Newman et al.,
2001; Buhler et al., 2009). In contrast, in the present work, we demon-
strated that upon lysolecithin-induced demyelination, MMP7 was
upregulated during remyelination, and also present in remyelinated MS
lesions. Furthermore, others have shown that MMP7 levels also remain
elevated during the remission phase of EAE (Kieseier et al., 1998). As
MMP7 efficiently degrades CSPGs and fibronectin, both known to
inhibit OPC maturation and transiently expressed upon demyelination
while being persistent in MS lesions (Lau et al., 2012; Stoffels et al.,
2013), MMP7 may aid to their timely degradation. In addition, since
MMP7 is able to degrade MBP (Chandler et al., 1995), this proteinase
may aid clearance of remyelination-inhibiting myelin debris. Neverthe-
less, MMP7 expression is not noticeably enhanced upon cuprizone-
induced demyelination, consistent with previous findings at the mRNA
level (Skuljec et al., 2011). Similar to Skuljec et al., we observed
increased expression of proMMP3 upon remyelination in the cuprizone
model. Hence, in addition to its detrimental effect in MS lesions, a sec-
ond local wave of MMP7 activity may be beneficiary by aiding remyeli-
nation by clearing OPC maturation-inhibiting ECM molecules and
degrading MBP in myelin debris. Of interest, is that pericellular MMP7-
mediated degradation of fibronectin is accelerated by cells that express
sulfatide on their surface (Yamamoto, Miyazaki, & Higashi, 2014).
Given that late-stage OPCs and mature oligodendrocytes are highly
enriched in surface sulfatide this may augment local fibronectin
degradation.
The enhanced MMP7 mRNA and protein expression upon neuro-
inflammatory conditions and lysolecithin-induced demyelination, which
is not evident upon cuprizone-induced demyelination, suggests that
MMP7 expression depends on the injury-mediated activation of local
cells. Indeed, expression of MMPs is regulated by a variety of biologi-
cally active agents, including growth factors, hormones and cytokines
(Clark, Swingler, Sampieri, & Edwards, 2008). Our results indicate that
alternative (IL-4-)activated microglia and macrophages, but not classical
(IFNg1LPS-)activated microglia and macrophages, secreted proMMP7
and proMMP9, but not proMMP3. Fibronectin degradation assays
demonstrated that alternative (IL-4-)activated macrophages and to
lesser extent microglia degraded fibronectin aggregates upon MMP-
activating conditions. This indicates that cells other than macrophages
and microglia are required to properly activate secreted proMMPs. For
example, proMMP7 is activated by MMP3 (Imai et al., 1995), which is
highly expressed by astrocytes upon demyelination (Skuljec et al.,
FIGURE 7 Degradation of aggregated fibronectin by conditioned medium. (a and b) Aggregated fibronectin (aFn, 5 mg) was incubated with
non-conditioned (–) or conditioned medium of control (ctrl), and IFNg1LPS2 and IL-4-actived bone marrow-derived macrophages and
microglia, or control and pro-inflammatory cytokine (TNFa, IFNg, and IL-1b) activated astrocytes for 72 hr at 378C and subjected to West-
ern blotting (non-reducing) using a polyclonal fibronectin (total Fn, a) or anti-EIIIA-fibronectin (EIIIA-Fn, b) antibody. MMPs present in
medium are not activated or activated by the general MMP activator APMA. Representative blots of three independent experiments are
shown. Arrow indicates main fibronectin degradation products
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2011). Yet, although the investigated cell types expressed proMMP3 in
vitro, and proMMP3 was particularly upregulated upon OPC matura-
tion, proMMP3 was hardly, if at all present in conditioned medium of
either cell type. Also, a central role for plasmin in the activation cascade
of MMPs is well documented (Lu et al., 2011), and may be a rate limit-
ing step in proper MMP7 activation. Furthermore, while proMMP7
was secreted by pro-inflammatory cytokine-activated astrocytes, fibro-
nectin aggregates remained virtually intact upon incubation with astro-
cyte conditioned medium at MMP-activating conditions. Our RT-qPCR
analysis showed that pro-inflammatory cytokines increased TIMP1 and
TIMP3 mRNA expression in astrocytes suggesting that such inhibitory
molecules may attenuate MMP activity, adding complexity to regula-
tion of local MMP7 activity.
The decreased MMP7 levels in chronic active and inactive MS
lesions may be due to dysfunctional activation of microglia and mac-
rophages. Indeed, microglia and macrophages in inflammatory MS
lesions have an intermediate activation status, expressing classical
and alternative activated phenotypes (Vogel et al., 2013; Peferoen
et al., 2015). The presence of alternative activated microglia/macro-
phages is essential for remyelination (Miron et al., 2013), and this
may rely on appropriate ECM remodeling (Agrawal et al., 2013).
Hence, therapeutically inducing local MMP7 expression in microglia/
macrophages may be an attractive approach to promote remyelina-
tion by resident OPCs in MS lesions. Intriguingly, in other cell types
in addition to IL-4, other inflammatory mediators, including IL-1,
IL-6, TGFb, and TNFa, have been implicated in the regulation of
MMP7 expression (Klein et al., 1997; Rosenberg, 2002ab; Kato,
Haro, Komori, and Shinomiya, 2004; Nagorsen et al., 2005; Clark
et al., 2008; Krstic & Santibanez, 2014).
MMP7-mediated cleavage of fibronectin aggregates was not suffi-
cient to overcome aggregate-induced inhibition of OPC maturation but
rather differentiation was decreased when OPCs were plated on
MMP7-treated fibronectin aggregate coatings, compared with intact
fibronectin aggregate coatings. This may be due to exposure of OPCs
to EIIIA/EDA-containing fragments, released upon MMP7-induced
cleavage of the aggregates. The EIIIA/EDA domain, particularly when it
is present as a fragment, acts as an endogenous ligand for TLR4 (Oka-
mura et al., 2001; Bhattacharyya et al., 2014). However, OPCs do not
express TLR4 (Lehnardt et al., 2003; Sloane et al., 2010; Bsibsi et al.,
2012), suggesting that upon release of EIIIA/EDA-containing fragment
the remaining aggregate may be remodeled, which altered the binding
and signalling activity to OPCs in a different fashion. Also, MMP7-
treated EIIIA-lacking plasma fibronectin coatings inhibited OPC differ-
entiation compared with intact plasma fibronectin, corroborating that
other fragments than an EIIIA-containing fragment inhibit OPC differ-
entiation. Therefore, the remaining aggregates may require further
processing and clearance by other proteases, e.g., MMP12 (Skuljec
et al., 2011), and/or phagocytosis. It is of particular interest in this
regard that fibronectin fragments, including EIIIA/EDA itself, can acti-
vate MMP expression (Saito et al., 1999; Yasuda et al., 2003).
TABLE 3 RT-qPCR analysis of primary microglia, bone marrow-derived macrophages and astrocytes
Microglia Macrophages Astrocytes
IFNc1LPS IL-4 IFNc1LPS IL-4 TNFa1IFNc1IL1b
MMP3 5.34 6 1.25* 0.76 6 0.06*** 9.16 6 2.56* 0.76 6 0.12 25.36 6 6.78***
MMP2 1.09 6 0.19 0.98 6 0.10 0.85 6 0.06 0.89 6 0.10 1.61 6 0.37
MMP7 0.52 6 0.16* 4.45 6 0.90* 0.27 6 0.04*** 3.17 6 0.38*** 2.96 6 1.46
MMP8 1.43 6 0.69 0.67 6 0.37 0.27 6 0.12*** 0.65 6 0.21 1.93 6 0.41
MMP9 1.57 6 0.31 1.34 6 0.23 1.06 6 0.16 1.04 6 0.12 15.87 6 5.72*
MMP11 0.72 6 0.14 0.87 6 0.10 1.02 6 0.22 1.18 6 0.13 0.72 6 0.22
MMP12 1.03 6 0.28 1.05 6 0.12 0.66 6 0.16 1.10 6 0.12 17.67 6 5.52*
MMP13 4.31 6 0.94* 0.96 6 0.11 2.44 6 0.53* 0.90 6 0.14 16.14 6 4.57*
MMP14 1.16 6 0.20 0.59 6 0.10* 1.05 6 0.18 0.54 6 0.10*** 0.87 6 0.13
ADAMST4 1.21 6 0.40 0.96 6 0.07 3.88 6 0.77* 0.67 6 0.12* n.d.
TIMP1 1.88 6 0.41 1.25 6 0.13 3.00 6 0.30*** 1.00 6 0.08 2.92 6 0.38***
TIMP2 0.60 6 0.05* 1.16 6 0.07 0.52 6 0.11* 1.11 6 0.03* 1.24 6 0.27
TIMP3 1.45 6 0.46 0.78 6 0.10 1.47 6 0.15* 1.00 6 0.22 2.27 6 0.42*
TIMP4 0.91 6 0.16 1.19 6 0.12 0.58 6 0.15 1.24 6 0.15 n.d.
tPA 4.2 6 1.60 1.51 6 0.30 1.80 6 0.36 0.72 6 0.05* 2.07 6 0.21***
uPA 3.51 6 2.19 2.00 6 1.00 0.59 6 0.43 0.82 6 0.08 3.62 6 1.68
All data relative to (untreated) control are shown, which was set to 1 at each independent experiment; Data are expressed as mean 6 SEM (n  4);
Statistical differences with control as assessed with a one sample t test are indicated (in bold, *p < .05. ***p < .001).
RT-qPCR5 real-time quantitative PCR.
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Thus, local addition, and specific and timely activation of MMP7
may be a therapeutic option to clear remyelination-inhibiting fibronec-
tin aggregates from MS lesions. However, due to potential side effects
such as MMP7-induced cleavage of (beneficial) laminin (Rosenberg,
2002a; Lu et al., 2011), MMP7-mediated activation of harmful cyto-
kines (Gearing et al., 1995; Yamamoto et al., 2014), or its toxicity to
axons (Newman et al., 2001), such an approach will require careful tar-
geting and timing of MMP7 activation. Accordingly, further knowledge
as to why the cleavage pattern of aggregated fibronectin differs from
that of plasma fibronectin, as well as identification of MMP7 cleavage
sites in the aggregates will be key to induce MMP7 to specifically
cleave aggregated fibronectin and enhance remyelination.
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